AEON

Several events have impacted AEON Biopharma's stock price in the past six months. The company received positive feedback from the FDA on its ABP-450 biosimilar program. AEON reported its full-year 2025 financial results, including positive comparative analytical results and FDA feedback, and announced a $6.0 million PIPE and a note exchange that reduced debt. AEON Biopharma received additional notices of non-compliance from NYSE American LLC related to continued listing standards. John Bencich was appointed as the Chief Financial Officer, effective April 1, 2026. Shareholders have experienced substantial dilution in the past year, with a 140% increase in shares outstanding. Over the past 12 months, the stock has gained 89.6%, but from the beginning of 2026, AEON shares have decreased by 18.2% and are currently trading around $0.90.